New Drugs Approved In November

in #approved • 7 years ago

11111.jpg

Cinvanti injectable emulsion
Cinvanti (aprepitant) injectable emulsion was approved by the FDA on November 9, 2017, for the prevention of acute and delayed Chemotherapy-Induced Nausea and Vomiting (CINV).

Developed by Heron Therapeutics, Inc. (HRTX), Cinvanti is the first and only polysorbate 80-free, intravenous formulation of an NK1 receptor antagonist and to directly deliver aprepitant, the active ingredient in Emend capsules.

Cinvanti, which is formulated as 130 mg aprepitant in 18 mL of emulsion in a single-dose vial for intravenous use, is planned for launch in the U.S. in January 2018.

#in #november #new #druge
7 years ago in #approved by
$0.00
    1 vote
    Reply 0

    Coin Marketplace

    STEEM 0.30
    TRX 0.33
    JST 0.054
    BTC 95529.89
    ETH 3818.47
    SBD 4.10